

WEST

Classification Search

Database to Search:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Classification System:

International Patent Classification (IPC)

Classification(s):

[Empty field]
 [Empty field]

Display:

15 Documents in Display Format: - Starting With #: 1

Generate:

☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Interrupt

Help

Logout

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

Search History

 DATE: Saturday, August 09, 2003 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L10</u>	L9 and I5	5	<u>L10</u>
<u>L9</u>	deoxy near cytidine	211	<u>L9</u>
<u>L8</u>	deoxy(4w)cytidine	0	<u>L8</u>
<i>DB=USPT; PLUR=YES; OP=ADJ</i>			
<u>L7</u>	deoxy(3w)cytidine	0	<u>L7</u>
<u>L6</u>	deoxy (2w)cytidine	0	<u>L6</u>
<u>L5</u>	L2 and hepatitis	85	<u>L5</u>
<u>L4</u>	L3 and Hepatitis	22	<u>L4</u>
<u>L3</u>	L2 and I1	74	<u>L3</u>
<u>L2</u>	((514/49)!.CCLS.)	349	<u>L2</u>
<u>L1</u>	((536/28.5)!.CCLS.)	280	<u>L1</u>

END OF SEARCH HISTORY

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623HXO

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS EXPRESS			April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:21:08 ON 09 AUG 2003

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:21:37 ON 09 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2003 HIGHEST RN 563538-18-1

DICTIONARY FILE UPDATES: 8 AUG 2003 HIGHEST RN 563538-18-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading cytidinehbv.str

L1 STRUCTURE UPLOADED

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:21:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2152 TO ITERATE

46.5% PROCESSED	1000 ITERATIONS	50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)		
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 40258 TO 45822

PROJECTED ANSWERS: 3967 TO 5845


L2 50 SEA SSS SAM L1

=> d scan


L2 50 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Cytidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-P-
[bis(1-methylethyl) amino]-P-deoxo-P-deoxythymidylyl-(3'.fwdarw.5')-2'-
deoxy- (9CI)
MF C44 H64 N11 O22 P3

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full

FULL SEARCH INITIATED 14:22:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 43518 TO ITERATE

100.0% PROCESSED 43518 ITERATIONS
SEARCH TIME: 00.00.01

6142 ANSWERS

L3 6142 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.95

149.16

FILE 'CAPLUS' ENTERED AT 14:23:23 ON 09 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2003 VOL 139 ISS 7

FILE LAST UPDATED: 8 Aug 2003 (20030808/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1/thu

SEARCH PROFILE NOT SUPPORTED FOR AUTOMATED SEARCH AND CROSSOVER

The search profile contains L-numbers or saved item names that include chemical substance terms, chemical structures, or structure screen sets. If you are in a single file environment using the CA file (CA, HCA, ZCA, CAPLUS, HCAPLUS, ZCAPLUS), enter HELP FIRST at an arrow prompt (=>) for information about the REGISTRY automated search and crossover feature. REGISTRY supports the following search profiles:

Example 1:

=> ACT SCRSTR/Q

L3 STR

L4 SCR 2127

L5 QUE L3 NOT L4

These searches are supported:

S L5/REG

S SCRSTR/Q/REG

S (L3 NOT L4)/REG

These searches are not supported:

S L5

S SCRSTR/Q

Example 2:

=> ACT SCRSTR2/Q

L6 STR

L7 SCR 2127

L8 QUE L6

L9 QUE L7
L10 QUE L8 NOT L9

This search is supported:

S (L6 NOT L7)/REG

These searches are not supported:

S L10
S L10/REG
S SCRSTR2/Q
S SCRSTR2/Q/REG
S L8 NOT L9
S (L8 NOT L9)/REG

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

149.58

FILE 'CAPLUS' ENTERED AT 14:24:12 ON 09 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2003 VOL 139 ISS 7

FILE LAST UPDATED: 8 Aug 2003 (20030808/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1/THU

SEARCH PROFILE NOT SUPPORTED FOR AUTOMATED SEARCH AND CROSSOVER

The search profile contains L-numbers or saved item names that include chemical substance terms, chemical structures, or structure screen sets. If you are in a single file environment using the CA file (CA, HCA, ZCA, CAPLUS, HCAPLUS, ZCAPLUS), enter HELP FIRST at an arrow prompt (=>) for information about the REGISTRY automated search and crossover feature. REGISTRY supports the following search profiles:

Example 1:

=> ACT SCRSTR/Q

L3 STR

L4 SCR 2127

L5 QUE L3 NOT L4

These searches are supported:

S L5/REG
S SCRSTR/Q/REG
S (L3 NOT L4)/REG

These searches are not supported:

S L5

S SCRSTR/Q

Example 2:

=> ACT SCRSTR2/Q

L6 STR
L7 SCR 2127
L8 QUE L6
L9 QUE L7
L10 QUE L8 NOT L9

This search is supported:

S (L6 NOT L7)/REG

These searches are not supported:

S L10
S L10/REG
S SCRSTR2/Q
S SCRSTR2/Q/REG
S L8 NOT L9
S (L8 NOT L9)/REG

=> d his

(FILE 'HOME' ENTERED AT 14:21:08 ON 09 AUG 2003)

FILE 'REGISTRY' ENTERED AT 14:21:37 ON 09 AUG 2003

L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM
L3 6142 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:23:23 ON 09 AUG 2003

FILE 'CAPLUS' ENTERED AT 14:24:12 ON 09 AUG 2003

=> s l3/thu

8438 L3
527224 THU/RL
L4 250 L3/THU
(L3 (L) THU/RL)

=> s l4 and hepatitis

39039 HEPATITIS
L5 22 L4 AND HEPATITIS

=> s l4 and virus

285813 VIRUS
61735 VIRUSES
296171 VIRUS
(VIRUS OR VIRUSES)
L6 76 L4 AND VIRUS

=> remove dup

DUP IS NOT VALID HERE

The DELETE command is used to remove various items stored by the system.

To delete a saved query, saved answer set, saved L-number list, SDI request, batch request, mailing list, or user-defined cluster, format, or search field, enter the name. The name may include ? for left, right, or simultaneous left and right truncation.

Examples:

DELETE BIO?/Q

- delete query names starting with BIO

DELETE ?DRUG/A	- delete answer set names ending with DRUG
DELETE ?ELEC?/L	- delete L-number lists containing ELEC
DELETE ANTICOAG/S	- delete SDI request
DELETE ENZYME/B	- delete batch request
DELETE .MYCLUSTER	- delete user-defined cluster
DELETE .MYFORMAT	- delete user-defined display format
DELETE .MYFIELD	- delete user-defined search field
DELETE NAMELIST MYLIST	- delete mailing list

To delete an ordered document or an offline print, enter its number.

Examples:

DELETE P123001C	- delete print request
DELETE D134002C	- delete document order request

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

DELETE L21	- delete a single L-number
DELETE L3-L6	- delete a range of L-numbers
DELETE LAST 4	- delete the last 4 L-numbers
DELETE L33-	- delete L33 and any higher L-number
DELETE -L55	- delete L55 and any lower L-number
DELETE L2-L6 RENUMBER	- delete a range of L-numbers and renumber remaining L-numbers
DELETE RENUMBER	- renumber L-numbers after deletion of intermediate L-numbers

Entire sets of saved items, SDI requests, batch requests, user-defined items, or E-numbers can be deleted.

Examples:

DELETE SAVED/Q	- delete all saved queries
DELETE SAVED/A	- delete all saved answer sets
DELETE SAVED/L	- delete all saved L-number lists
DELETE SAVED	- delete all saved queries, answer sets, and L-number lists
DELETE SAVED/S	- delete all SDI requests
DELETE SAVED/B	- delete all batch requests
DELETE CLUSTER	- delete all user-defined clusters
DELETE FORMAT	- delete all user-defined display formats
DELETE FIELD	- delete all user-defined search fields
DELETE SELECT	- delete all E-numbers
DELETE HISTORY	- delete all L-numbers and restart the session at L1

To delete an entire multifile SDI request, enter DELETE and the name of the request. To delete a component from the multifile SDI, enter DELETE and the name of the component.

=> dup

ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove

ENTER L# LIST OR (END):16

PROCESSING COMPLETED FOR L6

L7 76 DUP REMOVE L6 (0 DUPLICATES REMOVED)

=> dup
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remov
ENTER L# LIST OR (END):15
PROCESSING COMPLETED FOR L5
L8 22 DUP REMOV L5 (0 DUPLICATES REMOVED)

=> d 1-10 ibib hitstr 15



L5 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:133429 CAPLUS
DOCUMENT NUMBER: 138:210275
TITLE: Immunomodulatory compositions, formulations, and
methods for use thereof
INVENTOR(S): Fearon, Karen L.; Dina, Dino
PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014316	A2	20030220	WO 2002-US25123	20020807
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003133988	A1	20030717	US 2002-214799	20020807
PRIORITY APPLN. INFO.:			US 2001-310743P	P 20010807
			US 2001-335263P	P 20011025

OTHER SOURCE(S): MARPAT 138:210275
IT 499212-87-2 499212-89-4
RL: PAC (Pharmacological activity); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(immunomodulatory oligonucleotide compns. for use with microcarriers)

RN 499212-87-2 CAPLUS
CN Guanosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-P-thioguanilyl-
(3'.fwdarw.5')-2'-deoxy-P-thioadenilyl-(3'.fwdarw.5')-P-thiothymidylyl-
(3'.fwdarw.5')-2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.









RN 499212-89-4 CAPLUS

CN Thymidine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-P-thioguanilyl-(3'.fwdarw.5')-P-thiothymidylyl-(3'.fwdarw.5')-P-thiothymidylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





PAGE 2-A

PAGE 2-B




L5 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2003:6160 CAPLUS
 DOCUMENT NUMBER: 138:88635
 TITLE: Chimeric immunomodulatory compounds comprising nucleic acids linked through dendrimer or polysaccharide spacer and antigen for treating allergy, infection or cancer
 INVENTOR(S): Fearon, Karen L.; Dina, Dino; Tuck, Stephen F.
 PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
 SOURCE: PCT Int. Appl., 224 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000922	A2	20030103	WO 2002-US20025	20020621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-299883P	P 20010621
			US 2002-375253P	P 20020423


IT 15178-66-2P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (chimeric immunomodulatory compds. comprising nucleic acids linked through dendrimer or polysaccharide spacer and antigen for treating allergy, infection or cancer)
 RN 15178-66-2 CAPLUS
 CN Guanosine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:3466 CAPLUS
DOCUMENT NUMBER: 139:46447
TITLE: Assessment of the effect of phosphorylated metabolites of anti-human immunodeficiency virus and anti-hepatitis B virus pyrimidine analogs on the behavior of human deoxycytidylate deaminase
AUTHOR(S): Liou, Jieh-Yuan; Krishnan, Preethi; Hsieh, Cheng-Chih; Dutschman, Ginger E.; Cheng, Yung-Chi
CORPORATE SOURCE: Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA
SOURCE: Molecular Pharmacology (2003), 63(1), 105-110
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 1032-65-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of phosphorylated metabolites of anti-HIV and anti-hepatitis B virus pyrimidine analogs on human deoxycytidylate deaminase)
RN 1032-65-1 CAPLUS
CN 5'-Cytidylic acid, 2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:906175 CAPLUS
DOCUMENT NUMBER: 138:14074
TITLE: Preparation of benzo[g]quinoxalines for use against infectious diseases
INVENTOR(S): Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek,

Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe; Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach, Alexander; Habenberger, Peter
 PATENT ASSIGNEE(S): Axxima Pharmaceuticals Ag, Germany; et al.
 SOURCE: PCT Int. Appl., 237 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2001-112289	A 20010518
			US 2001-292325P	P 20010522
			US 2001-298902P	P 20010619
			EP 2001-115508	A 20010627

OTHER SOURCE(S): MARPAT 138:14074


IT 40093-94-5, Epcitabine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combined with benzo[g]quinoxalines for use against infectious diseases)

RN 40093-94-5 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:888486 CAPLUS

DOCUMENT NUMBER: 137:379972

TITLE: Nucleic acid-based compounds and methods of use in
 treatment of hepatitis virus infection,
 especially hepatitis B virus infection

INVENTOR(S): Iyer, Radhakrishnan P.; Jin, Yi; Roland, Arlene; Zhou,
 Wenqiang

PATENT ASSIGNEE(S): Origenix Technologies, Inc., Can.


SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2


DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092006	A2	20021121	WO 2002-US15383	20020515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003109471	A1	20030612	US 2002-146175	20020515
PRIORITY APPLN. INFO.:			US 2001-291471P	P 20010516
IT 70029-14-0 70029-14-0D, derivs. 475650-35-2 475650-35-2D, derivs. 475650-37-4 475650-37-4D , derivs. 475650-39-6 475650-39-6D, derivs. 475650-54-5 475650-54-5D, derivs. 475650-55-6 475650-55-6D, derivs. 475650-62-5 475650-62-5D , derivs. 475650-66-9 475650-66-9D, derivs. 475650-68-1 475650-68-1D, derivs. 475650-77-2 475650-77-2D, derivs. 475650-83-0 475650-83-0D , derivs. 475981-66-9 475981-66-9D, derivs. RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (oligonucleotide compds. for treatment of hepatitis virus infection)				
RN	70029-14-0 CAPLUS			
CN	Cytidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.

PAGE 1-A







RN 70029-14-0 CAPLUS

CN Cytidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-
(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 475650-35-2 CAPLUS

CN Adenosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-P-thiothymidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




NH_2

RN 475650-35-2 CAPLUS

CN Adenosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-P-thiothymidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 475650-37-4 CAPLUS
 CN Guanosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 475650-37-4 CAPLUS
 CN Guanosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.




RN 475650-39-6 CAPLUS
 CN Adenosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-P-thioguananylyl-
 (3'.fwdarw.5')--deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 475650-39-6 CAPLUS

CN Adenosine, 2'-deoxy-P-thiocytidyl- (3' to 5')-2'-deoxy-P-thioguananylyl- (3' to 5')-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-54-5 CAPLUS

CN Guanosine, P,2'-dideoxy-P-1-pyrrolidinylcytidyl-(3'.fwdarw.5')-2'-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-54-5 CAPLUS

CN Guanosine, P,2'-dideoxy-P-1-pyrrolidinylcytidyl-(3'.fwdarw.5')-2'-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-55-6 CAPLUS

CN Uridine, P,2'-dideoxy-P-1-pyrrolidinylcytidyl-(3'.fwdarw.5')-2'-O-methyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-55-6 CAPLUS

CN Uridine, P,2'-dideoxy-P-1-pyrrolidinylcytidyl-(3'.fwdarw.5')-2'-O-methyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-62-5 CAPLUS

CN Guanosine, P,2'-dideoxy-P-[[2-(4-morpholinyl)ethyl]amino]cytidyl-
(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-62-5 CAPLUS

CN Guanosine, P,2'-dideoxy-P-[[2-(4-morpholinyl)ethyl]amino]cytidyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-66-9 CAPLUS

CN Guanosine, P,2'-dideoxy-P-[[2-(diethylamino)ethyl]methylamino]cytidyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-66-9 CAPLUS

CN Guanosine, P,2'-dideoxy-P-[[2-(diethylamino)ethyl]methylamino]cytidyl-
(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-68-1 CAPLUS

CN Guanosine, P-[bis(phenylmethyl)amino]-P,2'-dideoxycytidyl-(3'.fwdarw.5')-
2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-68-1 CAPLUS

CN Guanosine, P-[bis(phenylmethyl)amino]-P,2'-dideoxycytidyl-(3'.fwdarw.5')-
2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-77-2 CAPLUS

CN Guanosine, P-[(1,3-benzodioxol-4-ylmethyl)amino]-P,2'-dideoxycytidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 475650-77-2 CAPLUS

CN Guanosine, P-[(1,3-benzodioxol-4-ylmethyl)amino]-P,2'-dideoxycytidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 475650-83-0 CAPLUS

CN Adenosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-P-(butylamino)-P-deoxythymidylyl-(3'.fwdarw.5')-2'-deoxy-, monoammonium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


● NH₃




RN 475650-83-0 CAPLUS

CN Adenosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-P-(butylamino)-P-deoxythymidylyl-(3'.fwdarw.5')-2'-deoxy-, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● NH₃



RN 475981-66-9 CAPLUS

CN Cytidine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-P-thioadenylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475981-66-9 CAPLUS

CN Cytidine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-P-thioadenylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:828620 CAPLUS
DOCUMENT NUMBER: 138:117630
TITLE: Oligonucleotide-mediated inhibition of hepatitis B
virus and hepatitis C virus replication
INVENTOR(S): Blatt, Lawrence; Macejak, Dennis; McSwiggen, James;
Morrissey, David; Pavco, Pamela; Lee, Patrice; Draper,
Kenneth; Roberts, Elisabeth
PATENT ASSIGNEE(S): Ribozyne Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 387 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 52
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081494	A1	20021017	WO 2002-XC9187	20020326
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA			

UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, ML, MR, NE, SN, TD, TG

AU 9851819 A1 19980611 AU 1998-51819 19980112
AU 729657 B2 20010208
AU 9939188 A1 19990916 AU 1999-39188 19990713
US 2003068301 A1 20030410 US 2001-877478 20010608
US 2003148985 A1 20030807 US 2002-310294 20021205

PRIORITY APPLN. INFO.:

US 2001-817879 A 20010326
US 2001-296876P P 20010608
US 2001-877478 A 20010608
US 2001-335059P P 20011024
US 2001-337055P P 20011205
US 1992-882712 B1 19920514
US 1994-193627 A1 19940207
AU 1995-26422 A3 19950518
US 1996-623891 A 19960325
US 1999-436430 A2 19991108
US 2000-531025 A2 20000320
US 2000-636385 A2 20000809
US 2000-696347 A2 20001024

L5 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:793628 CAPLUS

DOCUMENT NUMBER: 137:311149

TITLE: Solid phase synthesis and combinatorial library of
thiophosphate nucleic acids as antiviral agents

INVENTOR(S): Iyer, Radhakrishnan P.

PATENT ASSIGNEE(S): Origenix Technologies, Inc., Can.

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2002081476	A1	20021017	WO 2002-US10897	20020408
---------------	----	----------	-----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003087256	A1	20030508	US 2002-118480	20020408
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2001-282098P P 20010406

OTHER SOURCE(S): MARPAT 137:311149

IT 352669-45-5P 352669-49-9P 352669-53-5P

352669-57-9P 352669-78-4P 352669-82-0P

352669-86-4P 352669-90-0P

RL: CPN (Combinatorial preparation); IMF (Industrial manufacture); PAC
(Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); CMBI (Combinatorial study); PREP (Preparation); USES
(Uses)


(solid phase synthesis and combinatorial library of thiophosphate
nucleic acids as antiviral agents)

RN 352669-45-5 CAPLUS

CN Adenosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-,

3'-(dihydrogen phosphorothioate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352669-49-9 CAPLUS

CN Cytidine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-,
3'-(dihydrogen phosphorothioate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352669-53-5 CAPLUS

CN Guanosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-deoxy-,
3'-(dihydrogen phosphorothioate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352669-57-9 CAPLUS

CN Thymidine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-, 3'-(dihydrogen phosphorothioate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352669-78-4 CAPLUS

CN Adenosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-O-methyl-, 3'-(dihydrogen phosphorothioate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 352669-82-0 CAPLUS

CN Cytidine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-O-methyl-, 3'-(dihydrogen phosphorothioate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 352669-86-4 CAPLUS

CN Guanosine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-O-methyl-,
3'-(dihydrogen phosphorothioate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352669-90-0 CAPLUS

CN Uridine, 2'-deoxy-P-thiocytidylyl-(3'.fwdarw.5')-2'-O-methyl-,
3'-(dihydrogen phosphorothioate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:669670 CAPLUS
 DOCUMENT NUMBER: 137:185764
 TITLE: Preparation of amino acid-containing
 .beta.-L-2'-deoxy-nucleosides as antiviral agents for
 the treatment of **hepatitis B**
 INVENTOR(S): Gosselin, Gilles; Imbach, Jean-louis; Bryant, Martin
 L.
 PATENT ASSIGNEE(S): Novirio Pharmaceuticals Limited, Cyprus; Centre
 National Da La Recherche Scientifique
 SOURCE: U.S., 31 pp., Cont.-in-part of U.S. 6,395,716.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6444652	B1	20020903	US 1999-459150	19991210
US 6395716	B1	20020528	US 1999-371747	19990810
US 6566344	B1	20030520	US 2001-22148	20011214
US 6569837	B1	20030527	US 2001-22276	20011214

PRIORITY APPLN. INFO.:
 US 1998-96110P P 19980810
 US 1999-131352P P 19990428
 US 1999-371747 A2 19990810
 US 1999-459150 A1 19991210

OTHER SOURCE(S): MARPAT 137:185764


IT 40093-94-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of .beta.-L-2'-deoxy-nucleosides as antiviral agents for the
 treatment of **hepatitis B**)

RN 40093-94-5 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:414507 CAPLUS
 DOCUMENT NUMBER: 137:319926
 TITLE: Pharmacology of .beta.-L-thymidine and
 .beta.-L-2'-deoxycytidine in HepG2 cells and primary
 human hepatocytes: relevance to chemotherapeutic
 efficacy against **hepatitis B** virus
 AUTHOR(S): Hernandez-Santiago, B.; Placidi, L.; Cretton-Scott,
 E.; Faraj, A.; Bridges, E. G.; Bryant, M. L.;
 Rodriguez-Orengo, J.; Imbach, J. L.; Gosselin, G.;
 Pierra, C.; Dukhan, D.; Sommadossi, J. P.

CORPORATE SOURCE: Department of Pharmacology, University of Alabama at
Birmingham, Birmingham, AL, USA
SOURCE: Antimicrobial Agents and Chemotherapy (2002), 46(6),
1728-1733
CODEN: AMACCQ; ISSN: 0066-4804
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English


IT 40093-94-5

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.-L-thymidine and .beta.-L-2'-deoxycytidine intracellular metab.
in HepG2 cells and primary human hepatocytes in relation to
chemotherapeutic efficacy against hepatitis B virus)

RN 40093-94-5 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:10433 CAPLUS

DOCUMENT NUMBER: 136:79728

TITLE: Guanyl hydrazone inhibitors of hepatitis B
virus infection

INVENTOR(S): Bevec, Dorian; Obert, Sabine

PATENT ASSIGNEE(S): Axxima Pharmaceuticals A.-G., Germany

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000613	A2	20020103	WO 2001-EP7260	20010626
WO 2002000613	A3	20021107		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-214556P P 20000627

OTHER SOURCE(S): MARPAT 136:79728


IT 40093-94-5, Epcitabine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(guanyl hydrazone inhibitors of hepatitis B virus infection)

RN 40093-94-5 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> d 11-22 ibib hitstr 15

L5 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:923812 CAPLUS

DOCUMENT NUMBER: 136:42882

TITLE: Prodrugs of 2'-deoxy-.beta.-L-nucleosides

INVENTOR(S): Bryant, Martin L.; Gosselin, Gilles; Imbach,
Jean-Louis

PATENT ASSIGNEE(S): Novirio Pharmaceuticals Limited, Cayman I.; Centre
National de la Recherche Scientifique (CNRS)

SOURCE: PCT Int. Appl., 160 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096353	A2	20011220	WO 2001-US19147	20010615
WO 2001096353	A3	20020418		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1296995	A2	20030402	EP 2001-944522	20010615
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003083306	A1	20030501	US 2001-883033	20010615
BR 2001011732	A	20030624	BR 2001-11732	20010615
NO 2002006001	A	20030212	NO 2002-6001	20021213
PRIORITY APPLN. INFO.:			US 2000-212100P P	20000615
			WO 2001-US19147 W	20010615

OTHER SOURCE(S): MARPAT 136:42882

IT 380887-09-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);


PREP (Preparation); USES (Uses)

(prepn. and properties of prodrugs of 2'-deoxynucleosides as anti-hepatitis B agents)

RN 380887-09-2 CAPLUS

CN L-Valine, 3'-ester with 4-amino-1-(2-deoxy-.alpha.-L-erythro-pentofuranosyl)-2(1H)-pyrimidinone, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT 40093-94-5DP, derivs., esters 380886-95-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and properties of prodrugs of 2'-deoxynucleosides as anti-hepatitis B agents)

RN 40093-94-5 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 380886-95-3 CAPLUS

CN L-Valine, 3'-ester with 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-2(1H)-pyrimidinone (9CI) (CA INDEX NAME)

Absolute stereochemistry.






L5 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2001:885734 CAPLUS
 DOCUMENT NUMBER: 136:20220
 TITLE: Methods of treating **hepatitis** delta virus infection with .beta.-L-2'-deoxy-nucleosides
 INVENTOR(S): Sommadossi, Jean-Pierre; Bryant, Martin L.
 PATENT ASSIGNEE(S): Novirio Pharmaceuticals Limited, Cayman I.
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001091737	A2	20011206	WO 2001-US17301	20010529
WO 2001091737	A3	20020530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002035085	A1	20020321	US 2001-867110	20010529
US 6596700	B2	20030722		
EP 1292313	A2	20030319	EP 2001-937785	20010529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2000-207538P	P 20000526
			WO 2001-US17301	W 20010529
OTHER SOURCE(S): MARPAT 136:20220				
IT 40093-94-5P				
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use) ; BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of antiviral .beta.-L-2'-deoxy-nucleosides for treating hepatitis delta virus infection)				
RN 40093-94-5 CAPLUS				
CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-(9CI) (CA INDEX NAME)				

Absolute stereochemistry. Rotation (+).



L5 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:790095 CAPLUS

DOCUMENT NUMBER: 136:112013

TITLE: Antiviral .beta.-L-nucleosides specific for **hepatitis B** virus infection

AUTHOR(S): Standring, David N.; Bridges, Edward G.; Placidi, Laurent; Faraj, Abdesslem; Loi, Anna Giulia; Pierra, Claire; Dukhan, David; Gosselin, Gilles; Imbach, Jean-Louis; Hernandez, Brenda; Juodawlkis, Amy; Tennant, Bud; Korba, Brent; Cote, Paul; Cretton-Scott, Erika; Schinazi, Raymond F.; Myers, Maureen; Bryant, Martin L.; Sommadossi, Jean-Pierre

CORPORATE SOURCE: Novirio Pharmaceuticals, Cambridge, MA, USA

SOURCE: Antiviral Chemistry & Chemotherapy (2001), 12(Suppl. 1), 119-129

CODEN: ACCHEH; ISSN: 0956-3202

PUBLISHER: International Medical Press

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


IT 40093-94-5, NV 02C

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antiviral .beta.-L-nucleosides specific for **hepatitis B** virus infection)

RN 40093-94-5 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:674936 CAPLUS


DOCUMENT NUMBER: 136:47974

TITLE: Anti-HBV specific .beta.-L-2'-deoxynucleosides

AUTHOR(S): Bryant, Martin L.; Bridges, Edward G.; Placidi, Laurent; Faraj, Abdesslem; Loi, Anna-Giulia; Pierra, Claire; Dukhan, David; Gosselin, Gilles; Imbach,


Jean-Louis; Hernandez, Brenda; Juodawlkis, Amy;
Tennant, Bud; Korba, Brent; Cote, Paul; Cretton-Scott,
Erika; Schinazi, Raymond F.; Sommadossi, Jean-Pierre
CORPORATE SOURCE: Novirio Pharmaceuticals, Inc., Cambridge, MA, 02476,
USA
SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2001),
20(4-7), 597-607
CODEN: NNNAFY; ISSN: 1525-7770
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 40093-94-5 374107-79-6 381719-94-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(anti-HBV specific .beta.-L-2'-deoxynucleosides structure-activity
relationships)
RN 40093-94-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 374107-79-6 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-5-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 381719-94-4 CAPLUS
CN 2(1H)-Pyrimidinone, 4-amino-5-chloro-1-(2-deoxy-.beta.-L-erythro-
pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2001:247187 CAPLUS
 DOCUMENT NUMBER: 134:275762
 TITLE: Immunostimulatory nucleic acids
 INVENTOR(S): Krieg, Arthur M.; Schetter, Christian; Vollmer, Jorg
 PATENT ASSIGNEE(S): University of Iowa Research Foundation, USA; Coley
 Pharmaceutical G.b.m.H.
 SOURCE: PCT Int. Appl., 338 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022972	A2	20010405	WO 2000-US26383	20000925
WO 2001022972	A3	20020117		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1221955	A2	20020717	EP 2000-965433	20000925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014236	A	20021015	BR 2000-14236	20000925
JP 2003510282	T2	20030318	JP 2001-526182	20000925
EE 200200158	A	20030616	EE 2002-158	20000925
BG 106538	A	20021229	BG 2002-106538	20020321
NO 2002001453	A	20020527	NO 2002-1453	20020322
PRIORITY APPLN. INFO.:			US 1999-156113P	P 19990925
			US 1999-156135P	P 19990927
			US 2000-227436P	P 20000823
			WO 2000-US26383	W 20000925

OTHER SOURCE(S): MARPAT 134:275762

IT 77064-59-6 81742-55-4 89947-10-4
 104909-25-3 143304-96-5 207496-46-6
 207496-47-7 331871-08-0 331871-10-4
 331871-18-2 331871-21-7 331871-23-9
 331871-26-2 331871-36-4 331871-43-3
 331871-50-2 331871-57-9 331871-61-5
 331871-63-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); PRP (Properties); THU (Therapeutic use);
 BIOL (Biological study); USES (Uses)
 (immunostimulatory nucleic acids)

RN 77064-59-6 CAPLUS


CN Guanosine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-
 (3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-
 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A





PAGE 1-B







RN 81742-55-4 CAPLUS
 CN Cytidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-
 (3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-
 (3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-
 (3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxy- (6CI, 9CI) (CA
 INDEX NAME)

Absolute stereochemistry.









RN 89947-10-4 CAPLUS

Guanosine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-
 (3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-
 deoxycytidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.








RN 104909-25-3 CAPLUS
 CN DNA, d(C-C-C-C-C-C-C-C-C-C-C) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



NH_2






PAGE 2-C




PAGE 3-A



PAGE 3-B



PAGE 3-C




RN 143304-96-5 CAPLUS
CN Guanosine, 2'-deoxycytidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-


deoxyguanylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-
 deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-thymidylyl-
 (3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B









RN 207496-46-6 CAPLUS

CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-
 (3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-
 (3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.









RN 207496-47-7 CAPLUS
 CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-
 (3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-
 (3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-
 (3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 331871-08-0 CAPLUS

CN Guanosine, 2'-deoxycytidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.


PAGE 1-A

Me



PAGE 1-B









RN 331871-10-4 CAPLUS

CN Adenosine, 2'-deoxycytidyl-(3'.fwdarw.5')-2'-deoxyguanylyl-
(3'.fwdarw.5')-thymidyl-(3'.fwdarw.5')-2'-deoxycytidyl-(3'.fwdarw.5')-
2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.












RN 331871-18-2 CAPLUS

CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.









RN 331871-21-7 CAPLUS

Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-B




PAGE 2-A



PAGE 2-B







RN 331871-23-9 CAPLUS

CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-B




PAGE 2-A



PAGE 2-B









RN 331871-26-2 CAPLUS

CN Adenosine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-
 (3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-
 (3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.







RN 331871-36-4 CAPLUS
 CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-
 (3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-
 (3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)




Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 331871-43-3 CAPLUS

CN Adenosine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.









NH₂

RN 331871-50-2 CAPLUS
 CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-
 deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-
 deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-
 deoxycytidylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)



Absolute stereochemistry.







RN 331871-57-9 CAPLUS
 CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-
 (3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-
 (3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-
 (3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.









RN 331871-61-5 CAPLUS

CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-
 (3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-
 (3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-
 (3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.









RN 331871-63-7 CAPLUS

CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-2'-
deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-
deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-thymidylyl-
(3'.fwdarw.5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L5 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2001:247185 CAPLUS
 DOCUMENT NUMBER: 134:275777
 TITLE: Therapy for cancer and viral disease with a 2-5A
 oligoadenylate and interferon
 INVENTOR(S): Silverman, Robert H.; Rusch, Lorraine
 PATENT ASSIGNEE(S): Cleveland Clinic Foundation, USA
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022970	A1	20010405	WO 2000-US41038	20000929
WO 2001022970	C2	20020801		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,

YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1229920 A1 20020814 EP 2000-977293 20000929
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: US 1999-156542P P 19990929
 WO 2000-US41038 W 20000929


IT 332342-73-1P 332342-75-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (oligoadenylate and interferon for treatment of cancer and viral disease)

RN 332342-73-1 CAPLUS

CN Cytidine, 5'-O-(hydroxymercaptophosphinyl)adenylyl-(2'.fwdarw.5')-adenylyl-(2'.fwdarw.3')-2'-deoxy- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 332342-75-3 CAPLUS

CN Cytidine, 5'-O-(hydroxymercaptophosphinyl)adenylyl-(2'.fwdarw.5')-adenylyl-(2'.fwdarw.5')-adenylyl-(2'.fwdarw.3')-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2000:133703 CAPLUS
 DOCUMENT NUMBER: 132:166457
 TITLE: Preparation of .beta.-L-2'-deoxynucleosides for the treatment of **hepatitis B**
 INVENTOR(S): Gosselin, Gilles; Imbach, Jean-louis; Bryant, Martin L.
 PATENT ASSIGNEE(S): Novirio Pharmaceuticals Ltd., Cayman I.; Centre National de la Recherche Scientifique
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009531	A2	20000224	WO 1999-US18149	19990810
WO 2000009531	A3	20000615		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2340156	AA	20000224	CA 1999-2340156	19990810
AU 9954757	A1	20000306	AU 1999-54757	19990810
EP 1104436	A2	20010606	EP 1999-941027	19990810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9912896	A	20020213	BR 1999-12896	19990810
PRIORITY APPLN. INFO.:			US 1998-96110P	P 19980810
			US 1999-131352P	P 19990428
			WO 1999-US18149	W 19990810

OTHER SOURCE(S): MARPAT 132:166457


IT 40093-94-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .beta.-L-2'-deoxynucleosides for the treatment of **hepatitis B**)

RN 40093-94-5 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy-.beta.-L-erythro-pentofuranosyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:11450 CAPLUS

DOCUMENT NUMBER: 132:175374


TITLE: Characterization of the antiviral effect of 2',3'-dideoxy-2',3'-didehydro-.beta.-L-5-fluorocytidine in the duck **hepatitis B** virus infection model

AUTHOR(S): Le Guerhier, Franck; Pichoud, Christian; Guerret, Sylviane; Chevallier, Michele; Jamard, Catherine; Hantz, Olivier; Li, Xiu-Yan; Chen, Shu-Hui; King, Ivan; Trepo, Christian; Cheng, Yung-Chi; Zoulim, Fabien

CORPORATE SOURCE: INSERM Unit 271, Lyon, 69003, Fr.

SOURCE: Antimicrobial Agents and Chemotherapy (2000), 44(1), 111-122
 CODEN: AMACCQ; ISSN: 0066-4804
 PUBLISHER: American Society for Microbiology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 951-77-9D, Deoxycytidine, L-nucleoside analog
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiviral effect of dideoxydidehydrofluorocytidine in the duck hepatitis B virus infection model)
 RN 951-77-9 CAPLUS
 CN Cytidine, 2'-deoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1999:763900 CAPLUS
 DOCUMENT NUMBER: 132:11626
 TITLE: CpG oligonucleotides and other adjuvants for inducing mucosal immunity
 INVENTOR(S): McCluskie, Michael J.; Davis, Heather L.
 PATENT ASSIGNEE(S): Loeb Health Research Institute At the Ottawa Hospital, Can.; CPG Immunopharmaceuticals, Inc.
 SOURCE: PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961056	A2	19991202	WO 1999-US11359	19990521
WO 9961056	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2328894	AA	19991202	CA 1999-2328894	19990521
AU 9941977	A1	19991213	AU 1999-41977	19990521
AU 761899	B2	20030612		
EP 1077722	A2	20010228	EP 1999-925754	19990521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO
BR 9910643 A 20011030
JP 2002516294 T2 20020604
PRIORITY APPLN. INFO.:

BR 1999-10643 19990521
JP 2000-550515 19990521
US 1998-86393P P 19980522
WO 1999-US11359 W 19990521

IT 207496-46-6 207496-47-7


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as adjuvant for stimulation of mucosal immunity)




RN 207496-46-6 CAPLUS

CN Thymidine, 2'-deoxycytidyl-(3'.fwdarw.5')-2'-deoxyadenyl-(3'.fwdarw.5')-2'-deoxyadenyl-(3'.fwdarw.5')-2'-deoxycytidyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-thymidyl-(3'.fwdarw.5')-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 207496-47-7 CAPLUS
 CN Thymidine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-
 (3'.fwdarw.5')-2'-deoxyadenylyl-(3'.fwdarw.5')-2'-deoxyadenylyl-
 (3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-


(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





IT 15178-66-2D, d(CpG), oligonucleotides-contg.


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(stimulation of mucosal immunity by)

RN 15178-66-2 CAPLUS

CN Guanosine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)



Absolute stereochemistry.



L5 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1998:789027 CAPLUS
 DOCUMENT NUMBER: 130:37294
 TITLE: Vectors and methods for immunization or therapeutic protocols
 INVENTOR(S): Davis, Heather L.; Krieg, Arthur M.; Schorr, Joachim; Wu, Tong
 PATENT ASSIGNEE(S): Ottawa Civic Hospital Loeb Research Institute, Can.; University of Iowa Research Foundation; Qiagen G.m.b.H.
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852581	A1	19981126	WO 1998-US10408	19980520
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2301575	AA	19981126	CA 1998-2301575	19980520
AU 9876908	A1	19981211	AU 1998-76908	19980520
EP 1003531	A1	20000531	EP 1998-924828	19980520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6339068	B1	20020115	US 1998-82649	19980520
PRIORITY APPLN. INFO.:				
			US 1997-47209P	P 19970520
			US 1997-47233P	P 19970520
			WO 1998-US10408	W 19980520
IT 58927-25-6				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (DNA vaccine vector with removal of neutralizing CpG motifs and insertion of stimulatory CpG motifs as well as promoter/enhancer for enhancing expression of therapeutic protein)				
RN 58927-25-6 CAPLUS				
CN Guanosine, 2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxyguanylyl-(3'.fwdarw.5')-2'-deoxycytidylyl-(3'.fwdarw.5')-2'-deoxy- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:436524 CAPLUS

DOCUMENT NUMBER: 129:170141

TITLE: Anti-**hepatitis** B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-.beta.-L(-)-5-fluorocytidine

AUTHOR(S): Zhu, Yong-Lian; Dutschman, Ginger E.; Liu, Shwu-Huey; Bridges, Edward G.; Cheng, Yung-Chi

CORPORATE SOURCE: Department Pharmacology, Yale University School Medicine, New Haven, CT, 06520, USA

SOURCE: Antimicrobial Agents and Chemotherapy (1998), 42(7), 1805-1810

CODEN: AMACCQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 951-77-9D, Deoxycytidine, analogs


RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(anti-hepatitis B virus activity and metab. of
2',3'-dideoxy-2',3'-didehydro-.beta.-L(-)-5-fluorocytidine)

RN 951-77-9 CAPLUS

CN Cytidine, 2'-deoxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1995:756200 CAPLUS

DOCUMENT NUMBER: 123:160865

TITLE: Acylated pyrimidine nucleosides for treatment of toxicity from chemotherapeutic and antiviral agents

INVENTOR(S): Von Borstel, Reid Warren; Bamat, Michael Kevin

PATENT ASSIGNEE(S): Pro-Neuron, Inc., USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9426761	A1	19941124	WO 1993-US12689	19931230
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9460812	A1	19941212	AU 1994-60812	19931230
IN 177670	A	19970215	IN 1994-CA701	19940902
AU 9952624	A1	19991202	AU 1999-52624	19991001
PRIORITY APPLN. INFO.:			US 1993-61381	A 19930514
			IN 1992-CA473	A1 19920706
			WO 1993-US12689	W 19931230
			AU 1995-29150	A3 19950630

OTHER SOURCE(S): MARPAT 123:160865

IT 166961-84-8


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(acylated pyrimidine nucleosides for treatment of toxicity from chemotherapeutic and antiviral agents)

RN 166961-84-8 CAPLUS

CN Cytidine, 2'-deoxy-5-(1-oxohexadecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 951-77-9D, Deoxycytidine, acyl derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acylated pyrimidine nucleosides for treatment of toxicity from
chemotherapeutic and antiviral agents)

RN 951-77-9 CAPLUS

CN Cytidine, 2'-deoxy- (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.